Leerink Partners analyst David Risinger has maintained their bullish stance on LLY stock, giving a Buy rating today. David Risinger’s ...

Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of ...

In addition, Thaçi added, the “safety data support the long-term use of nemolizumab for the treatment of adolescent and adult patients with moderate to severe atopic dermatitis.” The current ...

On Friday, Eli Lilly and Company (NYSE:LLY) revealed new results from the Phase 3b ADapt study of Ebglyss (lebrikizumab), ...

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q3 2024 earnings call. [Operator ...

Ladies and gentlemen, thank you for standing-by, and welcome to the Lilly Q3 2024 Earnings Call. [Operator Instructions] I ...

Medscape Medical News, October 01, 2024 EADV 2024 Atopic Dermatitis Control on Biologic Persists Over 3 Years In a 3-year extension of the pivotal trials that provided lebrikizumab with an ...

Atopic dermatitis (AD) is a highly prevalent chronic ... often negatively affect their day-to-day and long-term well-being. Lebrikizumab, a monoclonal antibody that inhibits an interleukin named ...

APG777, an extended half-life monoclonal antibody targeting IL-13, a primary driver of AD, has shown equivalent or superior potency in preclinical studies compared to lebrikizumab. The drug's ...

Finally, in immunology, we're excited by the recent U.S. FDA approval of lebrikizumab as Ebglyss for adults and children 12 years and older with moderate-to-severe atopic dermatitis. Ebglyss ...

APG777, an extended half-life monoclonal antibody targeting IL-13, a primary driver of AD, has shown equivalent or superior potency in preclinical studies compared to lebrikizumab ... a promising drug ...